This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Comment: Licensing drugs post-Brexit amounts to surmountable administrative task

June 1, 2017, MLex

Robin Blaney is quoted in an MLex article regarding pleas from the EMA urging UK drugmakers to relicense their products in another EU country before Brexit. According to Blaney, the transfer of authorizations is "primarily an administrative exercise," and there is no legal obstacle to using a shell company in the European Economic Area to hold marketing authorizations. "Legally, there's no reason why your European regulatory department can't remain in the UK." The only individual who would certainly need to move to a country within the bloc is the EU QPPV, he says.

Share this article: